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Abstract 
Objective: Sporadic fatal adverse events have been reported during treatment of multiple sclerosis with alemtu-
zumab. To provide a systematic overview, we searched the centralized European Medicines Agency database of 
suspected adverse reactions related to medicinal products (EudraVigilance) for fatal adverse events associated with 
treatment with alemtuzumab (Lemtrada®) for multiple sclerosis. Four independent reviewers with expertise on MS, 
clinical immunology, infectious diseases and clinical pharmacology reviewed the reports, and scored the likelihood for 
causality.
Results: We identified nine cases with a probable and one case with a possible causal relationship between alem-
tuzumab treatment and a fatal adverse event. Six of these patients died within one month after treatment; one from 
intracerebral hemorrhage, two from acute multiple organ failure and septic shock, one from listeriosis, one from 
pneumonia and one from agranulocytosis. Four patients died several months after administration of alemtuzumab 
from either autoimmune hepatitis, immune-mediated thrombocytopenia, autoimmune hemolytic anemia or agranu-
locytosis. Four of the 10 cases had been published previously in case reports or congress abstracts. Fatal adverse 
events related to treatment with alemtuzumab occur more frequently than previously published in the literature. A 
significant proportion occurs in the first month after treatment.
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Introduction
Alemtuzumab is a humanized monoclonal antibody 
directed against CD52, and is regarded as one of the most 
efficacious drugs for treatment of relapsing–remitting 
multiple sclerosis (MS) [1]. Alemtuzumab induces a pro-
found decrease of T and B lymphocytes, with a gradual 
recovery starting one month after administration [2, 3]. 
Even though alemtuzumab is generally considered safe, 
serious adverse reactions have been identified, includ-
ing infections, immune-mediated thrombocytopenia and 
thyroiditis [3]. Following regulatory approval of alemtu-
zumab for relapsing remitting MS in 2013 by the Euro-
pean Medicines Agency (EMA) and in 2014 by the U.S. 
Food and Drug Administration (FDA), there have been 
reports of severe and even fatal suspected adverse effects. 
These include listeriosis [4, 5], alveolar hemorrhage [6], 
neutropenia with staphylococcus infection [7], autoim-
mune hemolytic anemia with necrotizing leukoencepha-
lopathy [8], and hemophagocytic lymphohistiocytosis [9].
These concerns led us to perform a systematic search 
for information on fatal cases following treatment with 
alemtuzumab in MS, retrieving data from the European 
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term “Multiple sclerosis, acute and progressive”, using 
the EudraVigilance Data Analysis System (EVDAS). Only 
reactions classified as “fatal” were included, as well as 
cases with the reaction outcome “fatal” and with Reac-
tion Seriousness Death set to “Yes”. The search included 
post-marketing spontaneous reports and reports from 
clinical studies from the European Economic Area, i.e. 
the European Union, Iceland, Liechtenstein and Norway.
Four reviewers with clinical and research experience in 
MS and neuroimmunology (LB and TH), clinical immu-
nology and infectious diseases (BF) and clinical pharma-
cology (OS), independently reviewed the full Council for 
International Organization of Medical Sciences (CIOMS) 
reports and case narratives reports and scored the likeli-
hood for causality in one of the four groups > 85%, 85–50%, 
50–35% or < 15%. The cases were then discussed and the 
fatal adverse event assessed as related or unrelated to alem-
tuzumab, using guidance from the FDA and the World 
Health Organization and Uppsala Monitoring Centre 
[10, 11]. Based on the known safety profile and biological 
effects of alemtuzumab, we considered immunosuppres-
sion, infection or hyperinflammation in close proximity 
of treatment, as well as secondary autoimmunity occur-
ring months after treatment, as plausible consequences of 
alemtuzumab. As previously described for the assessment 
of the association between acute acalculous cholecystitis 
and alemtuzumab [12], the related cases were further sub-
divided as either probable or possible from the plausibility 
and robustness of the evidence, including whether alterna-
tive explanations could be reasonably ruled out from the 
available data. Case reports lacking information essential 
for the assessment of causality, including the temporal rela-
tionship between alemtuzumab treatment and the adverse 
event, disease history or concomitant medication, or where 
duplication could not be excluded, were discarded.
Results
After exclusion of duplicates, including two cases of fatal 
autoimmune hepatitis occurring almost simultaneously in 
the same country which were not marked as duplications 
in the case reports, there were 17 unique cases. In 10 of 
these (nine female and one male) the fatal adverse events 
were considered to be related to alemtuzumab. Clinical 
characteristics of these cases are shown in Table  1. All 
these patients were adults. The age was not further speci-
fied for one case, the others ranged from 34 to 47 years.
In nine unique cases (No. 1–9 in Table 1) all reviewers 
considered that the fatal adverse event was probably to 
be caused by alemtuzumab. Six of the patients (No. 1–6) 
died within one month after alemtuzumab infusion. All 
patients who died within one month had only received 
one alemtuzumab cycle. Five of these patients (No. 2–6) 
died from infection or multiple organ failure and septic 
shock, whereas the sixth (No. 1) developed hypertension 
and a cytokine storm and died from an intracerebral hem-
orrhage five days after receiving the first alemtuzumab 
infusion. Autopsy revealed necrotizing vasculopathy, but 
did not confirm that the patient had MS. The reporting 
physician concluded that causality with alemtuzumab was 
unlikely, as cerebral hemorrhage was not a known adverse 
event of alemtuzumab. The patient had also received the 
antithrombotic drug certoparin sodium. Given the imme-
diate temporal relationship and the recent report of early 
strokes associated with alemtuzumab treatment from 
the FDA [13], we concluded that causality was probable. 
Notably, increasing blood pressure, which was reported in 
this patient, was recently suggested to be a characteristic 
feature of alemtuzumab-induced stroke [14].
The remaining three patients in whom a causal role of 
alemtuzumab were considered probable (No. 7–9) were 
all female, and died from secondary autoimmunity 8 to 
18 months after the last alemtuzumab infusion. Of these, 
one patient died from immune-mediated thrombocyto-
penia and brain stem hemorrhage, one from autoimmune 
hepatitis, and one from autoimmune hemolytic anemia, 
disseminated intravascular coagulation and septic shock. 
Immune-mediated thrombocytopenia was diagnosed 
several weeks prior to the intracranial hemorrhage, but 
did not respond to treatment with corticosteroids and 
intravenous immunoglobulins.
In five cases the fatal adverse event [suicide (n = 2), 
cancer (n = 2) and status epilepticus (n = 1)] were consid-
ered unlikely to be related to alemtuzumab. In addition, 
two cases were considered unclassifiable. These were 
neonates weighing less than 500 g, who both died within 
one day after induced labor. The mother had been treated 
with alemtuzumab during pregnancy.
The reviewers disagreed substantially on two cases. 
One patient (No. 10) developed agranulocytosis 
17 months after the second course of alemtuzumab, fol-
lowed by colitis, aspergillus pneumonia and death from 
multiple organ failure.  CD4+ T cells were also low prior 
to death. Two reviewers scored the likelihood of a causal 
relationship as < 50%. It was, however, agreed to empha-
size that neutropenia grade III or IV have been reported 
in 1.5% of MS patients in the second year after alemtu-
zumab treatment [15], and that it was plausible that neu-
tropenia in combination with low  CD4+ T cell counts 
induced by alemtuzumab contributed to aspergillus 
pneumonia and death. A causal relationship with alem-
tuzumab was therefore considered possible. The second 
patient, who had aggressive MS, developed status epi-
lepticus few days after alemtuzumab, followed by aspi-
ration pneumonia, sepsis and colon bleeding, and died 
after 40  days. In spite of a close temporal relationship 
with alemtuzumab most reviewers considered that status 
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epilepticus was more likely caused by aggressive MS, and 
that causality therefore was unlikely.
Discussion
We identified 9 case reports of MS patients with fatal 
adverse events considered to be probably caused by alem-
tuzumab, and one with a possible causal relationship. 
Four of these cases (No. 2 and 6–8) have previously been 
published or reported on meetings [4, 7, 16, 17], whereas 
six have not been published. Our results were shared 
with the Pharmacovigilance Risk Assessment Commit-
tee in EMA before EMA initiated an article 20 review of 
Lemtrada on April 12 2019.
As expected from the pharmacodynamic properties and 
known adverse drug reaction profile of alemtuzumab, fatal 
adverse events either occurred early and were character-
ized by immunosuppression, hyperinflammation or stroke, 
or occurred several months later and were characterized 
by secondary autoimmunity. Secondary autoimmunity is 
known to occur frequently after alemtuzumab treatment in 
MS patients, and is suggested to be mediated by the reap-
pearance of naïve immunologically active B cells while 
regulatory T cells are still suppressed [18]. All cases of fatal 
secondary autoimmunity occurred within a time frame that 
is compatible with such a hypothesis. It is also known that 
listeriosis occurs during the first weeks after treatment with 
alemtuzumab, possibly reflecting marked and transient 
acute effects on both the adaptive and innate immunity, 
including impaired function of remaining immune cells 
[19]. The underlying mechanisms of such acute reactions 
is believed to include a programmed release of cytokines 
from natural killer cells, triggered by Fc cross-linking [20].
After we performed our search, FDA issued a warning 
related to 13 cases of and hemorrhagic stroke or arte-
rial dissection occurring shortly after the patients had 
received alemtuzumab, mostly within one day after infu-
sion [13]. This, along with the recently published report of 
eight cases of acalculous cholecystitis in close time prox-
imity to alemtuzumab treatment [12], support a hypoth-
esis of hyperinflammation after alemtuzumab treatment 
despite routine prophylaxis with corticosteroids.
Immune-mediated thrombocytopenia occurs in approx-
imately 2% of MS patients treated with alemtuzumab [21]. 
It usually responds well to standard treatment with corti-
costeroids, although the fatal case reported here indicates 
that this is not always the case. The finding of only one 
case of immune-mediated thrombocytopenia with fatal 
outcome may however suggest that obligate screening for 
thrombocytopenia clearly limits the consequences of this 
adverse event. The same may be the case for glomerulone-
phritis, which was not recorded in this dataset.
Underreporting of adverse events is frequent, and even 
for severe adverse events it is estimated that only 1–10% 
of adverse events are reported [22]. Although underre-
porting may be less frequent for fatal adverse events, a 
PubMed search identified two fatal cases in Europe that 
were not registered in EudraVigilance [8, 9]. As some 
cases are likely neither published nor reported, the num-
ber of fatal adverse events in Europe may exceed the 12 
events identified by us.
Whereas patients are routinely screened for second-
ary autoimmunity every month for at least four years after 
receiving alemtuzumab, the first weeks after treatment have 
received relatively little attention. Our results indicate that 
life threatening adverse events could be more frequent dur-
ing this period. It should, however, be taken into considera-
tion that in general, associations between drug treatment 
and adverse events are more easily recognized, and there-
fore also more often reported, shortly after commencement 
of drug therapy. In our material, the initial events mostly 
included infections and hyperinflammation. Prophylactic 
treatment with antibiotics has been suggested in addition 
to the antiviral therapy that is generally used [23], and could 
perhaps prevent listeriosis more effectively than diet advice 
alone. Weekly hematological screening the first period fol-
lowing treatment could possibly limit the consequences of 
early agranulocytosis [7], and monitoring of blood pressure 
could possibly prevent early cerebral hemorrhages [14]. 
Early adverse effects due to hyperinflammation can, how-
ever, at present neither be predicted nor fully prevented.
Conclusions
Fatal adverse events related to treatment with alemtu-
zumab occur more frequently than previously published 
in the literature, and seem to be most common during 
the first month after treatment. Patients, physicians and 
regulatory authorities should be aware of the serious risks 
associated with alemtuzumab treatment, which must be 
weighed against the high and durable clinical efficacy.
Limitations
• We had not access to full medical records. Although 
the CIOMS reports were generally quite detailed, we 
may have missed relevant information.
• The number of multiple sclerosis patients treated 
with alemtuzumab is not in the public domain. We 
can therefore not calculate the frequency of fatal 
adverse events.
• We may have missed cases that have not been reported 
to EudraVigilance.
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